Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

Antitumor drugs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibody-Drug Conjugates (ADCs) (23) Drug Intermediate (12) Drug-Linker Conjugates for ADC (19) Peptide-Drug Conjugates (PDCs) (1) Radionuclide-Drug Conjugates (RDCs) (2) ADC Antibody (8) ADC Linker (2) ADC Payload (18) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (3) Antifolate (1) Apoptosis (36) Autophagy (7) Bacterial (5) Bcl-2 Family (4) Biochemical Assay Reagents (2) c-Kit (1) c-Met/HGFR (4) c-Myc (1) Carboxylesterase (CES) (2) Caspase (4) CD22 (1) CD276/B7-H3 (1) CDK (2) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (4) DNA/RNA Synthesis (3) EGFR (11) Endogenous Metabolite (12) ERK (3) Eukaryotic Initiation Factor (eIF) (1) Ferroptosis (1) FGFR (1) Folate Receptor (FR) (1) Fungal (2) G-quadruplex (1) Glutathione S-transferase (1) HBV (1) HCV (1) HDAC (1) Heme Oxygenase (HO) (2) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HIV (4) HSP (1) IGF-1R (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (7) JNK (1) Kinesin (1) Liposome (8) Malate Dehydrogenase (MDH) (1) MDM-2/p53 (4) Microtubule/Tubulin (31) Mitochondrial Metabolism (4) MMP (1) MNK (1) mTOR (1) Mucin (1) NF-κB (2) Oct3/4 (1) P-glycoprotein (6) p38 MAPK (4) Parasite (3) PD-1/PD-L1 (2) Phosphodiesterase (PDE) (1) Photosensitizer (1) PI3K (1) PPAR (1) PROTACs (1) Reactive Oxygen Species (ROS) (6) Reference Standards (6) Reverse Transcriptase (1) SARS-CoV (3) Sigma Receptor (1) Somatostatin Receptor (2) Src (1) STAT (2) TAM Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (2) Topoisomerase (11) Transmembrane Glycoprotein (1) Trk Receptor (1) TROP2 (3) TRP Channel (1) Tyrosinase (1) UGT (2) VEGFR (2) β-catenin (1)
By Research Areas:	Cancer (143) Infection (14) Inflammation/Immunology (11) Metabolic Disease (6) Neurological Disease (3)
Oligonucleotides:	Pegylated Lipids (6)

154

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Drug Metabolite Drug Intermediate Drug Isomer Drug Derivative Antibody-Drug Conjugates (ADCs) Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Drug-Linker Conjugates for ADC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10128

GE11 1 Publications Verification	Biochemical Assay Reagents	Inflammation/Immunology
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study .

HY-168489

OBI-992 drug-linker	Drug-Linker Conjugates for ADC	Cancer
OBI-992 drug-linker is a drug-linker conjugate composed of a TOP I inhibitor Exatecan (HY-13631) and a linker. OBI-992 drug-linker exhibits antitumor property in mouse models and can be used for synthesis of ADC OBI-992 .

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a	Antibody-Drug Conjugates (ADCs)	Cancer
Ifinatamab deruxtecan (DS-7300a) is an ADC that binds an anti-B7-H3 antibody to the DNA topoisomerase I inhibitory anti-tumor drug DXd. Ifinatamab deruxtecan has antitumor activity .

HY-N2493

Lawsone 2 Publications Verification	Fungal Apoptosis	Infection Cancer
Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research .

HY-W011556

N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate TCFH	Biochemical Assay Reagents	Others
N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate is a kind of biological coupling reagent, can be used for antitumor drugs sulphur alkali before medicine research .

HY-W007466

Cyclohexane-1,3-dione	Drug Intermediate	Cancer
Cyclohexane-1,3-dione is a drug intermediate, and its derivatives can exhibit significant tyrosine kinase inhibitory activity and anti-tumor activity .

HY-176455

ADC-5 drug-linker	Drug-Linker Conjugates for ADC	Cancer
ADC-5 drug-linker (Compound linker-payload 5) is a drug-linker conjugate for ADC with potent anti-tumor activity. ADC-5 drug-linker can be used to synthesize NLRP3 agonist 3 (HY-176452) .

HY-178819

NM-001	Integrin Drug Intermediate	Cancer
NM-001 is a theranostic prodrug that targets ανβ3 integrin. NM-001 consists of cRGD and GFLG peptides, a DCM fluorophore and Chlorambucil (HY-13593). NM-001 internalizes into lysosomes of tumor cells via the cRGD peptide, and generates NM-002 (HY-178820) and Chlorambucil through intracellular cleavage at the GFLG peptide by overexpressed Cathepsin B (CTSB). NM-001 exhibits green fluorescence under physiological conditions, and converts to NIR fluorescence by CTSB activation. NM-001 has significant antitumor activity with low toxicity in HeLa cell xenografts mouse models. NM-001 can be used for real-time drug release monitoring research .

HY-162462

Antitumor agent-151	Apoptosis	Cancer
Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC₅₀ = 0.79 μM) and antitumor activity in vitro (IC₅₀ = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis .

HY-N2493R

Lawsone (Standard)	Fungal Apoptosis	Infection Cancer
Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research .

HY-156411

NR-NO2	Bacterial	Cancer
NR-NO2 is a potential drug with targeted release and imaging-based guidance in *antitumor* research. NR-NO2 has an *anti-bacterial* effect .

HY-128753

D-Lyxose	Endogenous Metabolite Drug Intermediate	Metabolic Disease
D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-174277

Antitumor agent-203	ADC Payload Topoisomerase	Cancer
Antitumor agent-203 (compound 26) is a derivative of Exatecan (DX-8951) (HY-13631) and can be used to prepare *antibody-drug* conjugates (ADCs), as the ADC Cytotoxin** .

HY-175214

Antitumor photosensitizer-9	Reactive Oxygen Species (ROS) Photosensitizer	Cancer
Antitumor photosensitizer-9 is a near-infrared Photosensitizer (PS) with a high singlet oxygen production rate (relative rate = 1.79). Antitumor photosensitizer-9 exhibits strong phototoxicity against various cancer cells and induces ROS generation under light irradiation. Antitumor photosensitizer-9 inhibits tumor growth in vivo and exhibits excellent anticancer photodynamic therapy (PDT) efficacy at low drug and light doses. Antitumor photosensitizer-9 can be used in photodynamic therapy research .

HY-101150

DGN462	DNA Alkylator/Crosslinker ADC Payload	Cancer
DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

HY-171508

Mal-PNU-159682	Drug-Linker Conjugates for ADC	Cancer
Mal-PNU-159682 is a Drug-Linker Conjugates for ADC, composes of ADC linker (maleimide) and ADC cytotoxin PNU-159682 (HY-16700), and has anti-tumor activity .

HY-W778423

[Pt(DACH)(OH)2(ox)] Dihydroxy Oxaliplatin-Pt(IV)	Drug Intermediate	Cancer
[Pt(DACH)(OH)2(ox)] (Dihydroxy Oxaliplatin-Pt(IV)) is a Oxaliplatin (HY-17371)-based Pt(IV) scaffold. [Pt(DACH)(OH)2(ox)] reacts with N-hydroxysuccinimide (NHS) ester of Pyropheophorbide-a (HY-128973) to yield phorbiplatin. Phorbiplatin is a highly potent Pt(IV) antitumor prodrug .

HY-19474

Maytansinol Ansamitocin P-0	Microtubule/Tubulin ADC Payload Apoptosis	Cancer
Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research .

HY-128753S6

D-Lyxose-d	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Metabolic Disease
D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S7

D-Lyxose-d-1	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Metabolic Disease
D-Lyxose-d-1 is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-W004698

(2-Methoxypyrimidin-5-yl)boronic acid	Drug Intermediate	Others
(2-Methoxypyrimidin-5-yl)boronic acid is a drug intermediate that can serve as a key reactant in the Suzuki-Miyaura coupling reaction, and is used for the synthesis of isoquinoline ketone derivatives with anti-tumor activity .

HY-141602

Pinatuzumab vedotin anti-CD22-vc-MMAE; DCDT2980S	Antibody-Drug Conjugates (ADCs) CD22 Microtubule/Tubulin	Cancer
Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities .

HY-126643

Wedeloside	Mitochondrial Metabolism	Others Cancer
Wedeloside is a diterpenoid amino glycoside isolated from the plant Wedelia asperrima. Wedeloside is capable of inhibiting ADP-stimulated respiration in mitochondria and possesses potential anti-tumor activity. Wedeloside is applicable in drug development and toxicological research .

HY-170865

OncoFAP-GlyPro-MMAF	Drug-Linker Conjugates for ADC	Cancer
OncoFAP-GlyPro-MMAF is a Drug-Linker Conjugate for ADC with potent antitumor activity. OncoFAP-GlyPro-MMAF consists of Monomethylauristatin F (HY-15579) and a linker. OncoFAP-GlyPro-MMAF can be used for synthesis of ADCs .

HY-141598

Datopotamab deruxtecan 2 Publications Verification DS-1062; Dato-DXd	TROP2 Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a *trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug* conjugate (ADC)*. Datopotamab deruxtecan has a potent antitumor* activity .

HY-127079

Epothilone F	Microtubule/Tubulin	Cancer
Epothilone F is a Microtubule/Tubulin-stabilizing agent with anti-tumor activity. Epothilone F inhibits the proliferation of breast cancer cells, non-small cell lung cancer cells, drug-resistant ovarian cancer cells .

HY-176773

Mal-G(PEG8-Me)-AAN-NH2	ADC Linker	Cancer
Mal-G(PEG8-Me)-AAN-NH2 is a linker of the drug conjugate QHL-1618 (HY-176772). QHL-1618 has anti-tumor activity .

HY-171135

Cetuximab MMAE	Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin	Cancer
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .

HY-144880

SC209 3-Aminophenyl Hemiasterlin	ADC Payload Microtubule/Tubulin P-glycoprotein	Cancer
SC209 (3-Aminophenyl Hemiasterlin) is a 3-aminophenyl hemiasterlin derivative that serves as a cytotoxin for ADCs, targeting tubulin. SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. SC209 exhibits antitumor activity and can be used in the synthesis of ADC molecules .

HY-128753S3

D-Lyxose-13C-2	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Others
D-Lyxose- ¹³C-2 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S5

D-Lyxose-13C-4	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Others
D-Lyxose- ¹³C-4 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753R

D-Lyxose (Standard)	Reference Standards Endogenous Metabolite Drug Intermediate	Metabolic Disease
D-Lyxose (Standard) is the analytical standard of D-Lyxose. This product is intended for research and analytical applications. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S4

D-Lyxose-13C-3	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Others
D-Lyxose- ¹³C-3 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-15579A

MMAF hydrochloride Maximum Cited Publications 9 Publications Verification Monomethylauristatin F hydrochloride	Microtubule/Tubulin ADC Payload	Cancer
MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-179256

U-031	ADC Payload	Cancer
U-031 is an anti-tumor agent. U-031 can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. U-031 is commonly used in cancer research .

HY-P9985

Disitamab vedotin 3 Publications Verification RC48	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .

HY-P9921A

Trastuzumab emtansine (solution) 3 Publications Verification Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-148128

TAM470	Microtubule/Tubulin ADC Payload	Cancer
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .

HY-144497

HE-S2	PD-1/PD-L1 Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC	Infection Cancer
HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity .

HY-15579B

MMAF sodium Maximum Cited Publications 9 Publications Verification Monomethylauristatin F sodium	Microtubule/Tubulin ADC Payload	Cancer
MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-W478417

(R)-Etodolac	β-catenin	Cancer
(R)-Etodolac is an enantiomer of the non-steroidal anti-inflammatory drug etodolic acid (HY-76251), which can inhibit the transcriptional inhibition of β-catenin. (R)-Etodolac has anti-tumor activity and can be used in the research of hepatocellular carcinoma .

HY-15579

MMAF Maximum Cited Publications 9 Publications Verification Monomethylauristatin F	Microtubule/Tubulin ADC Payload	Cancer
MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-13554

Annamycin	Antibiotic	Infection Cancer
Annamycin is an antibiotic, that has high affinity for lipid membranes and can bypass the multidrug resistance protein-1 (MDR-1 ) mechanism of cellular drug resistance. Annamycin exhibits antitumor efficacy in multilamellar vesicles against solid tumor .

HY-B0067B

(R)-Amrubicin (R)-SM-5887	Topoisomerase	Cancer
(R)-Amrubicin ((R)-SM-5887) is an anthracycline that effectively treats lung cancer by intercalating into DNA and inhibiting topoisomerase II activity, which consequently hampers DNA replication as well as RNA and protein synthesis, leading to cell growth inhibition and apoptosis. This compound exhibits superior anti-tumor efficacy compared to traditional anthracycline drugs while lacking the cumulative cardiac toxicity typically associated with this drug class.

HY-164500

MC3629	Apoptosis Histone Methyltransferase	Cancer
MC3629 is an inhibitor of histone methyltransferase (EZH2) with anti-tumor activity. MC3629 inhibits SHH MB cancer cell proliferation and self-renewal and induces apoptosis. MC3629 can be used to study drug resistance in tumor aggressiveness .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted *antibody-drug* conjugate (ADC)*. ADCT-601 has anti-tumor* activity .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an *antibody-drug* conjugate (ADC)** based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .

HY-152963

Tisotumab vedotin	Antibody-Drug Conjugates (ADCs)	Inflammation/Immunology Cancer
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .

HY-123891

NS-062	EGFR	Cancer
NS-062 is an orally active, irreversible targeted covalent inhibitor for EGFR, and exhibits antiproliferative efficacy in drug-resistant double mutated H1975 cell with an IC₅₀ of 0.19 μM. NS-062 exhibits antitumor efficacy in mouse H1975 xenograft model .

HY-173182

Antitumor agent-200	Microtubule/Tubulin P-glycoprotein	Cancer
Antitumor agent-200 (Compound 2g) is a microtubule synthesis inhibitor. By binding to the colchicine site of tubulin, it causes G2/M cell cycle arrest and generates reactive oxygen species (ROS). Antitumor agent-200 exhibits significant inhibitory activity against MCF7/ADR and KBV200 cell lines with overexpression of P-glycoprotein (P-gp), with drug resistance indices (DRI) of 0.83 and 0.58 respectively. In the MCF-7 xenograft model, Antitumor agent-200 (25 mg/kg, intraperitoneal injection) can achieve a tumor growth inhibition rate of 57.2%. Antitumor agent-200 can be used in the research of the anti-cancer field .

Cat. No.	Product Name

HY-L107

Anti-Cancer Natural Product Library

1,851 compounds

With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers.

MCE offers a unique collection of 1,851 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.

HY-L080

Targeted Therapy Drug Library

106 compounds

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.

There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.

MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

HY-L084

Microbial Metabolite Library

895 compounds

Nature has been a source of medicinal products for millennia, with many useful active substances developed from plant sources. In the 20th century, the discovery of the penicillin was the starting point for drug discovery from microbial sources. Microorganisms， which have been considered to be a rich source of unique bioactive compounds, play an important role in the development of the chemistry of natural products and medical therapy. Microbial metabolites have proved to be affective antimicrobial agents, anti-tumor agents, enzyme inhibitors, anti-inflammatory agents, etc. Today, many microbial-originated antibiotics are available in the mark, and a large number of bioactive metabolites are used in medicine.

MCE provides a unique collection of 895 microbial metabolites, which is an important source of lead compounds and can be used for drug discovery.

HY-L110

Cyclic Peptide Library

92 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 92 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cat. No.	Product Name	Type

HY-171135

Cetuximab MMAE	Chromogenic Assays
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .

HY-177434

Precemtabart tocentecan

Precem-TcT; M 9140

Chromogenic Assays

Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Fluorescent Dye
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Fluorescent Dye
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-P9994

Pertuzumab zuvotolimod

SBT6050

Chromogenic Assays Humanized Antibody

Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-177442

DS-3939a

DS-3939

Chromogenic Assays

DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .

Cat. No.	Product Name	Type

HY-W011556

N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate TCFH	Biochemical Assay Reagents
N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate is a kind of biological coupling reagent, can be used for antitumor drugs sulphur alkali before medicine research .

HY-W007466

Cyclohexane-1,3-dione	Biochemical Assay Reagents
Cyclohexane-1,3-dione is a drug intermediate, and its derivatives can exhibit significant tyrosine kinase inhibitory activity and anti-tumor activity .

HY-W004698

(2-Methoxypyrimidin-5-yl)boronic acid	Biochemical Assay Reagents
(2-Methoxypyrimidin-5-yl)boronic acid is a drug intermediate that can serve as a key reactant in the Suzuki-Miyaura coupling reaction, and is used for the synthesis of isoquinoline ketone derivatives with anti-tumor activity .

HY-172497

DSPE-PEG2000-Mal-Cys-REKA	Drug Delivery
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-Mal-Cys-REKA	Drug Delivery
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-Mal-Cys-REKA	Drug Delivery
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-Mal-Cys-REKA	Drug Delivery
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Biochemical Assay Reagents
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Biochemical Assay Reagents
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-172280A

DSPE-PEG2000-octreotide	Drug Delivery
DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery .

HY-172280

DSPE-PEG1000-octreotide	Drug Delivery
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .

HY-172280C

DSPE-PEG3400-octreotide	Drug Delivery
DSPE-PEG3400-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG3400-Octreotide can be used for drug delivery .

HY-172280B

DSPE-PEG5000-octreotide	Drug Delivery
DSPE-PEG5000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG5000-Octreotide can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P10128

GE11 1 Publications Verification	Biochemical Assay Reagents	Inflammation/Immunology
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Peptides	Others Cancer
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10239A

Tyr3-Octreotate acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10449

M2 Peptide	Peptides	Cancer
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand *peptide*-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

Cat. No.	Product Name	Target	Research Area

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a	Antibody-Drug Conjugates (ADCs)	Cancer
Ifinatamab deruxtecan (DS-7300a) is an ADC that binds an anti-B7-H3 antibody to the DNA topoisomerase I inhibitory anti-tumor drug DXd. Ifinatamab deruxtecan has antitumor activity .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted *antibody-drug* conjugate (ADC)*. ADCT-601 has anti-tumor* activity .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an *antibody-drug* conjugate (ADC)** based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .

HY-P99045

Sacituzumab 3 Publications Verification	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-145627

Ozuriftamab vedotin BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Ozuriftamab vedotin (BA3021), an *antibody-drug* conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2)** humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent *antibody-drug* conjugate (ADC) to target maytansinoid tubulin*. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor* efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P99101

Vobramitamab AEX-4089; MGC026 antibody	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P99151

Brentuximab	ADC Antibody TNF Receptor	Cancer
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC₅₀ of 10 nM against human CD30+ cancer cells .

HY-P99045A

Sacituzumab (powder)	ADC Antibody TROP2	Cancer
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-P9994

Pertuzumab zuvotolimod SBT6050	Antibody-Drug Conjugates (ADCs) EGFR Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 *antibody-drug* conjugate (ADC)*. Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8* agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-P99740

Mirzotamab	CD276/B7-H3 ADC Antibody	Cancer
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-P99612

Farletuzumab ecteribulin MORAb-202	Antibody-Drug Conjugates (ADCs)	Cancer
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

HY-P991294

MGTA-117 Antibody	ADC Antibody	Cancer
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .

HY-P99712

Lonigutamab hz208F2-4	IGF-1R Apoptosis ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases sup>[2].

HY-P99974

Nab-Paclitaxel 1 Publications Verification Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007	Microtubule/Tubulin Apoptosis Autophagy	Cancer
Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2493

Lawsone 2 Publications Verification	Infection Quinones Lawsonia inermis L. Lythraceae Classification of Application Fields Source classification Plants Naphthalene Quinones Disease Research Fields	Fungal Apoptosis
Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Animals Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Others
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-128753

D-Lyxose	Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides	Endogenous Metabolite Drug Intermediate
D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-19474

Maytansinol Ansamitocin P-0	Alkaloids Microorganisms Other Alkaloids Source classification Disease Research Fields Cancer	Microtubule/Tubulin ADC Payload Apoptosis
Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research .

HY-W012531

2-Hydroxycinnamic acid	Infection Monophenols Cinnamomum cassia (L.) D. Don Classification of Application Fields Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Lauraceae Disease Research Fields	HIV SARS-CoV Endogenous Metabolite Bacterial
2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against *Staphylococcus aureus* and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC₅₀ of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

HY-W012531R

2-Hydroxycinnamic acid (Standard)	Monophenols Cinnamomum cassia (L.) D. Don Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Lauraceae	Reference Standards HIV SARS-CoV Endogenous Metabolite Bacterial
2-Hydroxycinnamic acid (Standard) is the analytical standard of 2-Hydroxycinnamic acid. This product is intended for research and analytical applications. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against *Staphylococcus aureus* and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC₅₀ of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

HY-N2493R

Lawsone (Standard)	Quinones Lawsonia inermis L. Lythraceae Source classification Plants Naphthalene Quinones	Fungal Apoptosis
Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research .

HY-126643

Wedeloside	Microorganisms Terpenoids Source classification Diterpenoids	Mitochondrial Metabolism
Wedeloside is a diterpenoid amino glycoside isolated from the plant Wedelia asperrima. Wedeloside is capable of inhibiting ADP-stimulated respiration in mitochondria and possesses potential anti-tumor activity. Wedeloside is applicable in drug development and toxicological research .

HY-128753R

D-Lyxose (Standard)	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite Saccharides	Reference Standards Endogenous Metabolite Drug Intermediate
D-Lyxose (Standard) is the analytical standard of D-Lyxose. This product is intended for research and analytical applications. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-19474R

Maytansinol (Standard) Ansamitocin P-0 (Standard)	Alkaloids Microorganisms Other Alkaloids Source classification	Reference Standards Microtubule/Tubulin ADC Payload Apoptosis
Maytansinol (Standard) is the analytical standard of Maytansinol. This product is intended for research and analytical applications. Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research[1][2].

HY-N0235

Bakuchiol 2 Publications Verification (S)-(+)-Bakuchiol	Monophenols Classification of Application Fields Leguminosae Source classification Phenols Psoralea corylifolia L. Plants Disease Research Fields Cancer	Carboxylesterase (CES) p38 MAPK Autophagy UGT
Bakuchiol is a phytoestrogen that can be obtained from psoralen seeds. Bakuchiol has been proven to be a non-competitive inhibitor of multiple enzymes, including UDP-glucuronosyltransferase 2B7 (UGT2B7) and human carboxylesterase 2 (hCE2) , with IC₅₀s values of 40.9 μM and 7.28 μM, respectively. Bakuchiol exhibits significant research and application potential in areas such as anti-inflammatory , antibacterial , antitumor therapies, as well as drug metabolism regulation.

HY-N0235R

Bakuchiol (Standard) (S)-(+)-Bakuchiol (Standard)	Monophenols Leguminosae Source classification Phenols Psoralea corylifolia L. Plants	Carboxylesterase (CES) Reference Standards p38 MAPK Autophagy UGT
Bakuchiol (Standard) is the analytical standard of Bakuchiol. This product is intended for research and analytical applications. Bakuchiol is a phytoestrogen that can be obtained from psoralen seeds. Bakuchiol has been proven to be a non-competitive inhibitor of multiple enzymes, including UDP-glucuronosyltransferase 2B7 (UGT2B7) and human carboxylesterase 2 (hCE2) , with IC₅₀s values of 40.9 μM and 7.28 μM, respectively. Bakuchiol exhibits significant research and application potential in areas such as anti-inflammatory , antibacterial , antitumor therapies, as well as drug metabolism regulation.

HY-W050154R

Kojic acid (Standard)	Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Parasite Tyrosinase NF-κB CDK
Kojic acid (Standard) is the analytical standard of Kojic acid. This product is intended for research and analytical applications. Kojic acid is a substance produced by Aspergillus oryzae, with various biological activities including antitumor, insecticidal, antibacterial, antioxidant, and radioprotective effects. Kojic acid exhibits tyrosinase inhibition activity by capturing copper ions that bind to the active site of tyrosinase, preventing its activation. Tyrosinase is a key enzyme in the biosynthesis of melanin, so kojic acid can block melanin production. Additionally, kojic acid shows potential inhibition of NF-κB activity in human keratinocytes, which may also be related to the anti-melanogenic effect induced by kojic acid. Kojic acid is effective when administered orally and can also be absorbed transdermally. Nano-carrier systems prepared with kojic acid demonstrate effective delivery of anticancer drugs. Kojic acid holds promise for research in cancer, infectious diseases, and skin whitening among other fields .

Cat. No.	Product Name	Chemical Structure

HY-145989S

Aminobenzenesulfonic auristatin E-d8
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .

HY-128753S6

D-Lyxose-d

D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S7

D-Lyxose-d-1

D-Lyxose-d-1 is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S3

D-Lyxose-13C-2

D-Lyxose- ¹³C-2 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S5

D-Lyxose-13C-4

D-Lyxose- ¹³C-4 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S4

D-Lyxose-13C-3

D-Lyxose- ¹³C-3 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-W012531S2

2-Hydroxycinnamic acid-d4

2-Hydroxycinnamic acid-d₄ is deuterium labeled 2-Hydroxycinnamic acid. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC₅₀ of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

HY-W766368

C6 Ceramide-13C2,d2

C6 Ceramide- ¹³C₂,d₂ (C6-Cer- ¹³C₂,d₂) is the deuterium labeled and ¹³C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

Cat. No.	Product Name		Classification